Low-dose oral type I interferons reduce early virus replication of murine cytomegalovirus in vivo

Journal of Interferon and Cytokine Research

Volumn 17, Issue 10, 1997, Pages 625-630

  Beilharz, Manfred W ^a   McDonald, Wade ^a   Watson, Mark W ^a   Heng, Jasmine ^a   McGeachie, John ^a   Lawson, Cassandra M ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CYTOMEGALOVIRUS; DATA ANALYSIS; DOSE RESPONSE; FEMALE; IMMUNE RESPONSE; IMMUNE SYSTEM; INOCULATION; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RELAPSE; STATISTICAL ANALYSIS; TREATMENT PLANNING; VIRUS INFECTION; VIRUS REPLICATION;

EID: 0030803798     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/jir.1997.17.625     Document Type: Article

References (23)

1. TYRING, S.K. (1992). Introduction to clinical use of interferons. In: Interferon: Principles and Medical Applications. S. Baron, F.D. Coppenhaver, W.R. Fleischmann, Jr., T.K. Hughes, Jr., G.R. Kumpel, D.W. Niescl, G.J. Stanton, and S.K. Tyring (eds.) Galveston: The University of Texas Medical Branch at Galveston, pp. 399-408.
2. BARON, S., TYRING, S.K., FLEISCHMANN, R.W. Jr., COPPENHAVER, D.H., NIESEL, D.W., KLIMPEL, G.R.M., STANTON, G.J., and HUGHES, T.K. (1991). The interferons. Mechanisms of action and clinical applications. JAMA 266, 1375-1383.
3. LUBLIN, F.D., WHITAKER, J.N., EIDELMAN, B.H., MILLER, A.E., ARNASON, B.G.W., and BURKS, J.S. (1996). Management of patients receiving interferon beta-1b for multiple sclerosis: report of a consensus conference. Neurology 46, 12-18.
4. DE WIT, R. (1992). Kaposi's sarcoma and AIDS. In: Interferon: Principles and Medical Applications. S. Baron, F.D. Coppenhaver, W.R. Fleischmann, Jr., T.K. Hughes, Jr., G.R. Klimpel, D.W. Niesel, G.J. Stanton, and S.K. Tyring (eds.) Galveston: The University of Texas Medical Branch at Galveston, pp. 475-485.
5. GREENWAY, H. (1992). Cutaneous tumors: condyloma, basal cell carcinoma, squamous cell carcinoma and melanoma. In: Interferon: Principles and Medical Applications. S. Baron, F.D. Coppenhaver, W.R. Fleischmann, Jr., T.K. Hughes, Jr., G.R. Klimpel, D.W. Niesel, G.J. Stanton, and S.K. Tyring (eds.) Galveston: The University of Texas Medical Branch at Galveston, pp. 519-532.
6. PLATANIAS, L.C., and GOLOMB, H.M. (1992). Clinical use of interferons: hairy cell, chronic myelogenous and other leukemias. In: Interferon: Principles and Medical Applications. S. Baron, F.D. Coppenhaver, W.R. Fleischmann, Jr., T.K. Hughes, Jr., G.R. Klimpel, D.W. Niesel, G.J. Stanton, and S.K. Tyring (eds.) Galveston: The University of Texas Medical Branch at Galveston, pp. 487-499.
7. KOECH, D.K., and OBEL, A.O. (1990). Efficacy of Kemron (low-dose oral natural human interferon alpha) in the management of HIV-1 infection and acquired immune deficiency syndrome (AIDS). E. Afr. Med. J. 67, SS64-SS70.
8. OBEL, A.O., and KOECH, D.K. (1990). Outcome of intervention with or without low dose oral interferon alpha in thirty-two HIV-1 seropositive patients in a referral hospital. E. Afr. Med. J. 67, SS71-SS76.
9. KAISER, G., JAEGER, M., BIRKMAN, J., POPPINGER, J., CUMMINS, J.M., and GALLEIER, W.M. (1992). Low-dose oral natural human interferon-α in 29 patients with HIV infection: a double-blind, randomized, placebo-controlled trial. AIDS 6, 563-569.
10. SPERBER, S.J., GOCKE, D.J., HABERZETTL, C.A., and PESTKA, S. (1993). Low-dose oral recombinant interferon-αA in patients with HIV-1 infection: a blinded pilot study. AIDS 7, 693-697.
11. BROD, S.A., and KHAN, M. (1996). Oral administration of IFN-α is superior to subcutaneous administration of IFN-α in the suppression of chronic relapsing experimental autoimmune encephalomyelitis. J. Autoimm. 9, 11-20.
12. ALLAN, J.E., and SHELLAM, G.R. (1984). Genetic control of murine cytomegalovirus infection: virus titers in resistant and susceptible strains of mice. Arch. Virol. 81, 139-150.
13. LAWSON, C.M., GRUNDY, J.E., and SHELLAM, G.R. (1988). Antibody responses to murine cytomegalovirus in genetically resistant and susceptible strains of mice. J. Gen. Virol. 69, 1987-1998.
14. LAI, M.C., BEILHARZ, MAV., SCALZO, A.A., GARRET, K.L., CANNON, J.F., BOYER, S.J., and SWAMINATHAN, N. (1992). Structure/function studies of murine interferon-alpha 1 using site-directed mutagenesis followed by in vitro synthesis. Antiviral Res. 18, 65-76.
15. RAJ, N.B.K., ISRAELI, K., KELLY, K.A., LEACH, S.J., MINASIAN, E., SIKARIS, K., PARRY, D.A.D., and PITHA, P.M. (1988). Synthesis, antiviral activity, and conformational characterization of mouse-human-alpha-interferon hybrids. J. Biol. Chem. 263, 8943-8952.
16. MOORE, B.M., KRAKOKA, S., CUMMINS, J.M., and ROBERTSON, J.T. (1996). Changes in airway inflammatory cell populations in standard bred racehorses after interferon-alpha administration. Vet. Immunol. Immunopathol. 49, 347-358.
17. FLEISCHMANN, R.W., Jr., FIELDS, E.E., WANG, J.L., HUGHES, T.K., and STANTON, G.J. (1991). Modulation of peripheral leukocyte counts in mice by oral administration of interferons. Proc. Soc. Exp. Biol. Med. 197, 424-430.
18. FLEISCHMANN, R.W., and FLEISCHMANN, C.M. (1992). Mechanisms of interferons' antitumor action. In: Interferon: Principles and Medical Applications. S. Baron, F.D. Coppenhaver, W.R. Fleischmann, Jr., T.K. Hughes, Jr., G.R. Klimpel, D.W. Niesel, G.J. Stanton, and S.K. Tyring (eds.) Galveston: The University of Texas Medical Branch at Galveston, pp. 299-309.
19. FLEISCHMANN, R.W., Jr., KOREN, S., and FLEISCHMANN, C.M. (1992). Orally administered interferons exert their white blood cell suppressive effects via a novel mechanism. Proc. Soc. Exp. Biol. Med. 201, 200-207.
20. VAN DER VEN, I., and SMINIA, T. (1993). The development and structure of mouse nasal-associated lymphoid tissue: an immunoand enzyme-histochemical study. Regional Immunol. 5, 69-75.
21. FINTER, N.B., and OLDHAM, R.K. (1982). In vivo and clinical studies. Interferon 4, 146-147.
22. TOUGH, D.F., BORROW, P., and SPRENT, J. (1996). Induction of bystander T cell proliferation by viruses and type I interferon in vivo. Science 272, 1947-1950.
23. DEGRE, M. (1974). Influence of exogenous interferon on the peripheral white blood cell count in mice. Int. J. Cancer 14, 699-703.